6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGNPRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2022.

Commission File Number: 001-39071

ADC Therapeutics SA

(Exact name of registrant as specified in itscharter)

Biopôle

Route de la Corniche 3B

1066 Epalinges

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBIT INDEX

Exhibit 99.1

ADC Therapeutics Announces Abstracts to be Presentedat the European Hematology Association 2022 Hybrid Congress

Oral presentation of pivotal Phase 2 clinicaltrial of Cami in relapsed or refractory Hodgkin lymphoma

ZYNLONTA® diffuselarge B-cell lymphoma data highlighted in several abstracts

LAUSANNE, Switzerland, May 12, 2022 – ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation at the European Hematology Association 2022 Hybrid Congress (EHA2022), which will be held virtually and in Vienna, Austria from June 9-12, 2022.

“We continue to be encouraged by the data from our ongoing pivotal Phase 2 trial demonstrating the efficacy and safety of Cami as a single agent for patients with relapsed or refractory Hodgkin lymphoma,” said Joseph Camardo, MD, Chief Medical Officer of ADC Therapeutics. “As we advance Cami toward a potential BLA submission, we look forward to sharing these data with the hematology community at EHA2022.”

Details of ADC Therapeutics’ oral presentation are as follows:

Camidanlumab Tesirine: Updated Efficacy And SafetyIn An Open-Label, Multicenter, Phase 2 Study Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (R/R CHL)Presentation Date and Time: Friday, June 10, 2022, 11:45am – 12:00 pm CEST // 5:45 am – 6 am EDT Presentation Date and Time: Friday, June 10, 2022, 11:45am – 12:00 pm CEST // 5:45 am – 6 am EDTSession Title: Hodgkin lymphoma – ClinicalSession Room: Hall A8Abstract Code: S201Presenter: Carmelo Carlo-Stella,MD, Department of Biomedical Sciences, Humanitas University, and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital,Milan, ItalyDetails of ADC Therapeutics’ poster presentationsare as follows:Health-Related Quality Of Life And Tolerability OfLoncastuximab Tesirine In High-Risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated In A Phase 2 Clinical Trial(LOTIS 2)Session Date and Time: Friday, June 10, 2022, 16:30– 17:45 CEST // 10:30 am – 11:45 am EDTLocation: Hall DAbstract Code: P1717Real-World Characteristics And Clinical OutcomesIn Relapse/Refractory Diffuse Large B-Cell Lymphoma Patients Who Received Car-T TherapySession Date and Time: Friday, June 10, 2022, 16:30– 17:45 CEST // 10:30 am – 11:45 am EDTLocation: Hall DAbstract Code: 1182Real-World Characteristics And Clinical OutcomesIn Relapse/Refractory Diffuse Large B-Cell Lymphoma Post Car-T FailureSession Date and Time: Friday, June 10, 2022, 16:30– 17:45 CEST – 10:30 am – 11:45 am EDTLocation: Hall DAbstract Code: 1181 Titles of ADC Therapeutics’ abstracts acceptedfor publication only are as follows:| · | A Phase 2, Open-Label Study Of Loncastuximab Tesirine In Combination With Rituximab (LONCA-R) In Previously Untreated Unfit/Frail<br>Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9) [Trials in progress] || --- | --- || · | Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma<br>(DLBCL) || --- | --- || · | Phase 3 Randomized Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With<br>R/R DLBCL (LOTIS-5) [Trials in progress] || --- | --- |Please note: times and locations are tentativeand subject to change.About Camidanlumab Tesirine (Cami)Camidanlumab tesirine (Cami) is an antibody drug conjugate (ADC) comprisedof a monoclonal antibody that binds to CD25 (HuMax^®^-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD)dimer payload, tesirine. Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-basedpayload, killing the cell. This applies to CD25-expressing tumor cells and also to CD25-expressing Tregs. The intra-tumoral release ofits PBD payload may also cause bystander killing of neighboring tumor cells, and PBDs have also been shown to induce immunogenic celldeath. All of these properties of Cami may enhance immune-mediated anti-tumor activity.Cami is being evaluated in a pivotal Phase 2 clinical trial in patientswith relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solidtumors.About ZYNLONTA^®^ (loncastuximab tesirine-lpyl)ZYNLONTA^®^ is a CD19-directed antibody drug conjugate (ADC). Oncebound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. Thepotent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately resultsin cell cycle arrest and tumor cell death.The U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximabtesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines ofsystemic therapy, including DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma.The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease,including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triplehit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approvedby the FDA under accelerated approval based on overall response rate and continued approval for this indication may be contingent uponverification and description of clinical benefit in a confirmatory trial.ZYNLONTA is also being evaluated as a therapeutic option in combinationstudies in other B-cell malignancies and earlier lines of therapy.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology companyimproving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transformthe treatment paradigm for patients with hematologic malignancies and solid tumors.ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl)is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy.ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTAand Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.ADC Therapeutics is based in Lausanne (Biopôle), Switzerlandand has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/and follow the Company on Twitter and LinkedIn.ZYNLONTA^®^ is a registered trademark of ADC TherapeuticsSA.CONTACTS:InvestorsEugenia LitzADC TherapeuticsEugenia.Litz@adctherapeutics.com+44 7879 627205Amanda HamiltonADC Therapeuticsamanda.hamilton@adctherapeutics.com+1 917-288-7023EU MediaAlexandre MüllerDynamics Groupamu@dynamicsgroup.ch+41 (0) 43 268 3231USA MediaMary Ann OndishADC Therapeuticsmaryann.ondish@adctherapeutics.com+1 914-552-4625